Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

E I Du Pont De Nemours And Co (DD): New Life for an Ancient Company

Page 1 of 2

Back in 1802, when President Jefferson was trudging around the White House, E I Du Pont De Nemours And Co (NYSE:DD) was born. It’s since moved from an initial concentration in gunpowder manufacturing into the vast world of chemicals, and now to its latest manifestation in agricultural and food-related products.

The most recent transmogrification has clearly gained momentum since Ellen Kuhlman assumed its CEO mantel five years ago. It’s hard to see that directional change doing anything but intensifying.

E I Du Pont De Nemours And Co (NYSE:DD)

In that context, it’s probably not unrealistic to assume that, in another five years, the company will be devoting virtually all of its efforts creating the bio-engineered seeds, pesticides, and other products that will play key roles in feeding the 2 million additional folks who are expected to join us on Planet Earth in the next several decades. In fact, E I Du Pont De Nemours And Co (NYSE:DD) is already in a league with Monsanto Company (NYSE:MON), which had a head start in reinventing itself as a largely agriculture company, and now does little else.

For that very reason, it’s been especially edifying for me to peruse the transcript of a presentation by Jim Borel, a E I Du Pont De Nemours And Co (NYSE:DD) executive vice president, with responsibility for the company’s agricultural and nutrition businesses. At mid-week, Borel addressed analysts at the RBC Capital Markets Global Industrials Conference in Las Vegas.

The action never ceases

Before I pass along some of Borel’s specific comments about E I Du Pont De Nemours And Co (NYSE:DD)’s agriculture and nutrition segments, let’s review the bidding on some of the recent structural changes that have been completed, or are pending, at DuPont:

1). In 2011, E I Du Pont De Nemours And Co (NYSE:DD) paid $6.3 billion, including debt assumptions, for Danisco, a global enzyme and specialty food ingredients company based in Denmark.

2). Last year, DuPont sold its car paint unit to the Carlyle Group LP (NASDAQ:CG), a private equity firm, for $5 billion.

3). Also in 2012, DuPont acquired the remaining 28% it didn’t already own in Solae, a St. Louis-based developer of soy-based ingredients.

4). Last month, following an arduous three-year process, the company completed a transaction that gave it 80% of South Africa’s Pannar Seed. It thereby has gained an entree to effect much-needed agricultural improvements and efficiencies on that giant continent.

5). With its Performance Chemicals segment suffering major declines in both revenues and operating income during the most recent quarter, it’s a safe bet that the laggard operation will belong to someone else within the reasonably near term. A sale of the unit likely would fetch about $10 billion.

Real indications of progress

With those significant events as a backdrop, let’s now look at some of Borel’s key comments about DuPont’s progress in the agricultural and nutrition segments:

1). Between 2010 and 2012, the ag businesses outstripped its peers, growing at an annual 15% rate.

2). The Dansco acquisition has become accretive to the company far faster than was expected, having added about $0.25 to 2012 EPS.

3). In crop protection, the company is already nearing $900 million in revenues from “our blockbuster insect control products called Rynaxypyr.” (There will be a spelling test.) Beyond that, it has recently added two other unpronounceable, but effective, disease-control products to its repertoire.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!